Regeneron Pharmaceuticals

American pharmaceutical company

REGN Nasdaq ISIN US75886F1075 SEC CIK 872589 LEI 549300RCBFWIRX3HYQ56
Follow Regeneron Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $5.1B +36.3% vs same quarter last year
Net income $1.9B +33.5% vs same quarter last year
EPS, diluted $18.45 +35.5% vs same quarter last year
Operating cash flow $1.8B +10.2% vs same quarter last year
Revenue by quarter
$3.8B
$3B
$3.7B
$3.8B
$3.9B
$3.6B
$4.3B
$5.1B
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$5B$0$5B$10B$15B$20BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$14.3B$4.5B
FY24$14.2B$4.4B
FY23$13.1B$4B
FY22$12.2B$4.3B
FY21$16.1B$8.1B
FY20$8.5B$3.5B
FY19$6.6B$2.1B
FY18$5.1B$2.4B
FY17$5.9B$1.2B
FY16$4.9B$895.5M
FY15$4.1B$636.1M
FY14$2.8B$338.1M
FY13$2.1B$413.7M
FY12$1.4B$750.3M
FY11$445.8M−$221.8M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−50%0%50%100%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25-24.9%31.4%
FY24-28.1%31.1%
FY23-30.9%30.1%
FY22-38.9%35.6%
FY21-55.7%50.2%
FY20-42.1%41.3%
FY1993.9%33.7%32.3%
FY1895.4%49.3%47.5%
FY1796.6%35.4%20.4%
FY1696%27.4%18.4%
FY1594.1%30.5%15.5%
FY1495.4%29.2%12%
FY1394.4%35.3%19.7%
FY1293.9%33.2%54.4%
FY1199.1%−46%−49.7%
Free cash flowOperating cash flow minus capital expenditure
−$2B$0$2B$4B$6B$8BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25$4.1B
FY24$3.7B
FY23$3.9B
FY22$4.4B
FY21$6.5B
FY20$2B
FY19$2B
FY18$1.8B
FY17$1B
FY16$974M
FY15$652.8M
FY14$419.4M
FY13$432.3M
FY12−$124M
FY11−$198.9M
Returned to shareholdersDividends paid and shares bought back
  • Dividends
  • Buybacks
$0$2B$4B$6BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearDividendsBuybacks
FY25$370.3M$3.4B
FY24$0$2.6B
FY23$0$2.2B
FY22-$2.1B
FY21-$1.6B
FY20-$5.8B
FY19-$275.9M
FY18-$4.4M
FY17-$0
FY16-$0
FY15--
FY14--
FY13--
FY12--
FY11--
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Regeneron Pharmaceuticals
  • Healthcare median
−100%−50%0%50%100%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRegeneron PharmaceuticalsHealthcare median
FY2531.4%−30.6%
FY2431.1%−47%
FY2330.1%−58%
FY2235.6%−80.4%
FY2150.2%−71.9%
FY2041.3%−62.2%
FY1932.3%−46.3%
FY1847.5%−49.6%
FY1720.4%−45.9%
FY1618.4%−36%
FY1515.5%−38.4%
FY1412%−35.5%
FY1319.7%−37.1%
FY1254.4%−29.1%
FY11−49.7%−27.9%